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Transmembrane proteinThe viral peptide fusion inhibitor Fuzeon (T-20/DP178/enfuvirtide) is an essential part of the drug
combination that has signiﬁcantly increased the quality of life and life span of many acquired immuno-
deﬁciency syndrome (AIDS) patients. Its development as a drug preceded the elucidation of its precise
inhibitory mechanism, as well as its molecular targets. The initial model was that Fuzeon inhibits human
immunodeﬁciency virus (HIV) entry by targeting one site within the viral transmembrane envelope protein.
Herein, we describe the emerging discoveries that extend this model towards a multifaceted mechanism for
the drug in targeting HIV. This signiﬁcantly advances the understanding of how viruses enter host cells and
opens a new window of opportunity for designing future viral fusion inhibitors.+972 8 9344112.
i).
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Acquired immunodeﬁciency syndrome (AIDS) was discovered in
1981 [1,2], and is a major threat to human health since. The cause of
AIDS was identiﬁed in 1983 [3–5] and later was named the human
immunodeﬁciency virus (HIV). HIV is the most known membrane
enveloped retrovirus [6] which mainly infects cells from the immune
system; T-cells and macrophages [7,8]. In 2010, the joint UnitedNations program on HIV/AIDS (UNAIDS) published a report on the
global AIDS pandemics. This report indicated that around 33.3 million
people live with HIV. Each year 2.6 million people are infected by the
virus and 1.8 million die from AIDS. There is no cure or a vaccine for
this disease, and currently the treatment involves combinatorial anti
retroviral therapy targeting several steps in the virus life cycle [9]. This
treatment strategy has dramatically elongated the life span of patients
and results in a change from a progressive lethal disease to a chronic
condition with slow disease progression [10]. The magnitude of this
epidemic and the challenge to develop an effective treatment has led
to an extensive research on the molecular mechanisms of compounds
which inhibit different stages in the life cycle of the virus [11,12].
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The ﬁrst step in human immunodeﬁciency virus (HIV) infection is
fusion between the membranes of the virus and the host cell, leading
to the insertion of the viral genetic material into the cytoplasm.
Following reverse transcription, the viral cDNA is integrated into the
chromosomes of the cell [11]. The membrane fusion step is mediated
by the viral envelope glycoprotein (ENV) [13–16] (Fig. 1a). Like other
type I viral fusion proteins, the HIV ENV adopts trimeric organization
on the viral surface [17,18]. It is composed of two non-covalently
associated subunits: The gp120 subunit enables cell receptors and co-
receptors binding, while the gp41 transmembrane subunit endows
the physical membrane fusion [19–21]. The extracellular part
(ectodomain) of gp41 includes different regions that are involved in
membrane fusion (Fig. 1b): (i) the fusion peptide (FP), a hydrophobic
stretch at the N-terminus of the gp41 [22,23], (ii) the fusion peptide
proximal region (FPPR) [24], (iii) the N-terminal heptad repeat (NHR)
which creates a coiled-coil structure [25–27], (iv) the loop which
reverses the polypeptide chain [28,29], (v) the C-terminal heptad
repeat (CHR), a region which also creates a coiled-coil struc-
ture [30,31], (vi) the membrane proximal external region (MPER)
[32,33], and another hydrophobic region at the C-terminus of the
protein, the transmembrane domain (TMD) [34]. The intracellular
part of gp41 is also involved in membrane fusion and comprised of a
cytoplasmic tail (Cyt) [35].
The model of HIV membrane fusion asserts the conversion
between at least three major ENV conformations. Firstly, the ENV is
in its metastable native state on the virion surface [36,37]. In this state
gp41 is considered to be sheltered by gp120. Secondly, binding of
gp120 to CD4 and co-receptor (such as CXCR4 and CCR5) involves
conformational changes in both gp120 and gp41 resulting in the pre-
hairpin conformation [36,38,39]. At this point, gp41 is exposed anda
b
Fig. 1. Entry of HIV into its host cells. (a) The ﬁrst step in retrovirus infection is fusion betw
genetic material. The trimeric ENV of HIV mediates the fusion event [15,16,88,89]. It is comp
transmembrane subunit endows the physical membrane fusion [21,90]. (b) Organization of
(FP); fusion peptide proximal region (FPPR); N-terminal heptad repeat (NHR); loop; C-termi
domain (TMD) and cytoplasmic tail (Cyt). Regions within gp41 that are discussed in the reextended leading to the insertion of the FP into the host cell
membrane [23,40,41]. Thirdly, additional conformational changes
generate the hairpin conformation [17]. This conformation comprises
a trimeric central coiled-coil that is created by three NHR regions, into
which three CHR regions pack in an anti-parallel manner. This
structure is usually referred to as the “six helix bundle” or “core”
structure and it is suggested to be essential for complete membrane
merger as well as pore formation [33,42–44] (see structure in detail in
Fig. 2 a, b).3. The discovery of Fuzeon
The ﬁrst indications for functional regions in gp41 originated from
studies predicting a coiled-coil structure in its N- and C-termini [45].
Synthetic peptides are used tomodel coiled-coils, therefore, a peptide,
DP107, corresponding to the N-terminal region of gp41 was
synthesized. It exhibited a strong α-helical structure in solution
validating its coiled-coil nature [46]. The authors also tested the
ability of the peptide to inhibit HIV replication and demonstrated
inhibitory capabilities. Following the prediction of a high α-helical
secondary structure for another region, in the C-terminus of gp41,
another peptide, Fuzeon (T-20/DP178/enfuvirtide), was synthesized
and analyzed [47]. In contrary to DP107 it was unstructured in solution
but surprisingly, much more potent in inhibiting the virus. Fuzeon did
not affect the function of HIV reverse transcriptase, or protease, and it
was established that the peptide functions at an early stage of viral
replication, consistent with inhibiting the fusion ability of the virus
[48,49]. From that stage the work with Fuzeon diverged into the
followingdirections; theﬁrst, involved research towards understanding
the inhibition mechanism of the peptide, while the second focused on
developing the compound as a therapeutic drug [50].een the membranes of the virus and the host cell, leading to the insertion of the viral
osed of two subunits; gp120 subunit endows CD4 and co-receptors binding, while gp41
the ENV transmembrane subunit, gp41. The domain abbreviations are: fusion peptide
nal heptad repeat (CHR); membrane proximal external region (MPER); transmembrane
view are indicated. Residues are numbered according to the HXB2 gp160 variant.
a b c
Fig. 2. The hairpin structure of gp41. The very recent high resolution structure (PDB ID: 2x7r) [33] provides an insight into (i) the central core which is created by a trimeric inner
coiled-coil of three NHR regions, into which three CHR regions pack in an antiparallel manner, and (ii) the fusion peptide and the membrane proximal external regions (FPPR and
MPER, respectively). A top (a) and side (b) view of the structure is presented. C, carboxyl terminus; N amino terminus. In section b, the trimeric inner coiled-coil of the NHR is
highlighted in red and the three packing CHR regions are highlighted in green. The FPPR is highlighted in yellow and the MPER is highlighted in blue. (c) The same structure as in
section b with the location of Fuzeon which is highlighted in orange. Fuzeon overlaps two functionally different regions from the ectodomain of gp41. The N-terminus of the peptide
overlaps the CHR region while its C-terminus overlaps the hydrophobic MPER.
2354 A. Ashkenazi et al. / Biochimica et Biophysica Acta 1808 (2011) 2352–23584. Fuzeon comprises a unique sequence location
The peptide Fuzeon is unique amongst other fusion inhibitors in its
sequence location. It partially overlaps two functionally different
regions from the ectodomain of gp41, the CHR and the MPER (Figs. 1b
and 2c).
4.1. The CHR region
The CHR region contains a pocket-binding domain (PBD) that
includes three conserved hydrophobic residues. These residues bind
to a deep cavity termed “the pocket” on the outer surface of the NHR
coiled-coil structure. This is believed to be crucial for the six helix
bundle stability [51]. Also, the CHR contains a NHR-binding domain
consisting of hydrophobic amino acid heptad repeats [43]. Fuzeon
includes the NHR-binding domain and lacks the PBD [30,31] (Fig. 1b).
4.2. The MPER
The MPER of gp41 is rich in speciﬁcally tryptophan amongst other
hydrophobic residues. It is also the target of broadly neutralizing anti-
HIV-1 antibodies suggesting an important role for this region in gp41-
mediated membrane fusion [52–54]. It has been demonstrated
already in 1999 that this region is important for virus fusion and
infectivity [55]. Deletion of 17 amino acids or mutations of tryptophan
residues to alanines abrogated the ENV ability to induce cell–cell
fusion and viral entry. In contrast, the ENV maturation, transport and
CD4 binding properties were unaltered. The importance of the
conserved tryptophan residues was indicated to be at the level of
glycoprotein incorporation into virions. It was speculated that the
tryptophan residues interact with components of themembrane, such
as cholesterol, that result in glycoprotein enrichment in the
membrane subdomains through which the virus buds [55]. Later, it
was established that the MPER serves as a lipid domain targeting
sequence that causes membrane destabilization, and gp41 clustering
at the fusion site [56]. Utilizing cryoelectron microscopy tomography,
the structures of ENV spikes on the membranes of SIV and HIV-1
virions were discovered; the ﬁrst [18] supports binding of the MPER
region to the membrane of the virus, whereas the second [57]
supports inter-subunit interactions of this region. A recent crystal
structure of the HIV-1 gp41 core including the MPER (Fig. 2) providesthe evidence that part of MPER will be membrane inserted within
trimeric gp41 [33].
5. The molecular targets and inhibition mechanism of Fuzeon
5.1. Targeting the NHR region of gp41 and acquiring viral resistance
It was demonstrated already in 1994 [49] that Fuzeon blocks an
early step in the virus replication cycle prior to reverse transcription.
It was suggested that the peptide interferes with virus entry or
uncoating. Later on, a research showed that the helical structure of the
N-peptide, DP107, was disrupted in a dose dependent manner
following the addition of Fuzeon, indicating a possible interaction
between these two regions. Fuzeon peptides with alterations or
mutations demonstrated reduced interactive ability with DP107 and
exhibited reduced anti-viral activity [58]. Using Fuzeon, researchers
capture an early conformation of gp41 [38]. They showed that the
peptide binds gp41 and inhibits HIV-cell fusion after gp120 interacts
with cellular receptors. These studies provide insights into early
events leading to ENV-mediated membrane fusion.
Additional evidence for this mode of action lies in studies
examining viral strains that are resistant to Fuzeon. Resistant strains
were derived by serial virus passage in the presence of increasing
doses of the peptide [59]. A contiguous three amino acid sequence
within the NHR region, GIV (aa 547–549), was associated with the
resistance phenotype. This phenomenon of resistant strains with
alterations in that speciﬁc region was also observed during phase I of
the clinical trial with Fuzeon [60]. However their analysis, as well as
others, suggests that mutations in adjacent residues also contribute to
the resistance [61,62]. There are several proposed escapemechanisms
for the peptide resistant strains depending on the type of mutation in
the NHR region: reduced contact, steric obstruction, electrostatic
repulsion, and electrostatic attraction [63].
Using a six helix bundle speciﬁc monoclonal antibody with isolate-
restricted ENV reactivity, it was directly shown that Fuzeon binds to
the gp41 NHR coiled-coil to form a peptide/protein hybrid struc-
ture [64]. These observations led to a broad belief that this peptide
inhibits the virus replication cycle by blocking six helix bundle
formation, and preventing progression from the pre-hairpin confor-
mation to the hairpin conformation resulting in inhibiting virus–cell
membrane fusion (Fig. 3).
Fig. 3. Fuzeon inhibits multiple intermediate conformations within the viral ENV. Early on, it targets the gp120 co-receptor binding sequence, blocking the interaction of gp120–CD4
complexes with the CXCR4 co-receptor [65,68,77]. This prevents the conversion into the pre-hairpin conformation. Later, Fuzeon targets the NHR in gp41 pre-hairpin conformation
thus preventing the conversion into the hairpin conformation [61,64,72]. Lastly, it inhibits late fusion events which subsequently prevent fusion pore expansion [44,66,67].
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Several discoveries expand the initial inhibitory model of Fuzeon
that relies on prevention of the six helix bundle formation by
targeting the NHR region. First, the peptide does not contain the PBD
(Fig. 1b) that was previously demonstrated to be crucial for fusion
ability and six helix bundle stability [51]. Second, virus strains
resistant to Fuzeon are still sensitive to other CHR derived peptides
such as T649 [65] raising the possibility of an additional inhibitory
mode of action. Indications for additional inhibitory modes of action
began to surface, and in 1998, the ﬁrst study that presented strong
evidence for it was published [44]. The authors monitored the fusion
between effector cells (containing HIV-1 ENV) and target cells
(containing the receptors and co-receptors) labeled with lypophilic
and cytosolic ﬂuorescent probes. Upon addition of Fuzeon they
monitored inhibition of the cytosolic probe redistribution while the
lypophilic probes were redistributed freely. In a second study [66] it
was also demonstrated that Fuzeon binds and oligomerizes on the
surface of membranes. The authors concluded that the peptide has
two binding sites with different binding afﬁnities; the lower afﬁnity
site is the NHR, while the higher afﬁnity site is yet unknown. It was
speculated that the higher afﬁnity site is the parallel endogenous
region, and that by binding to it Fuzeon prevents aggregation of
several ENV trimers needed to enlarge the fusion pore. Therefore,
binding to the high afﬁnity site is associated with transition from the
lipid mixing state to the content mixing state. This conclusion was
further supported by a study demonstrating that the peptide inhibits
the late steps of membrane fusion after the lipid mixing stage [67].
The claim that Fuzeon has more than one binding site on gp41 was
also demonstrated by blocking its inhibitory activity by peptides
derived from the TMD of gp41. The TMD is thought to be a possible
second site in gp41 for Fuzeon binding [68].
5.3. Targeting the cell membrane
It has been demonstrated that the forces governing protein–
protein interactions in a membrane environment are different from
those in a solution environment. Speciﬁcally, the constraints involving
speciﬁc recognition based on chirality are not necessarily applicable
[22,69]. Based on this knowledge, Fuzeon variants with substitutionsto D-amino acids in either their N- or C-termini were designed [70]. It
was shown that substitution in the N-terminal region of the peptide
severely decreased the ability of the variant to inhibit fusion, while
such substitution in the C-terminus did not. This demonstrated the
involvement of the C-terminal region in membrane binding. Addition-
ally, monitoring the changes in membrane dipole potential demon-
strated an interaction of Fuzeon with erythrocyte and lymphocyte
membranes [71].
Strong evidence for the membrane binding ability of the peptide
was provided in a study published in 2007 [72]. Therein, the entire C-
terminal region of the peptide was truncated leading to loss of
activity. Strikingly however, replacement of the truncated amino acids
with a fatty acid resulted in the recovery of the activity. The activity of
the conjugated peptide correlated to the fatty acid carbon chain
length, to its concentration on cells, and to the directionality of fatty
acid conjugation (N- or C-terminus). The studies involving fatty
acid conjugation to Fuzeon variants [72,73] demonstrated that the
nC-terminal region of the peptide functions also as an anchor to the
cell membrane enabling its N-terminus to inhibit fusion by interacting
with the endogenous NHR coiled-coil.
5.4. Targeting the gp120 co-receptor binding sequence
The involvement of gp120 in the susceptibility to Fuzeon is
supported by several lines of evidence. A reduced susceptibility to the
peptide was demonstrated by chimeric viruses containing a CCR5 V3
loop compared with the CXCR4 parent strains [74,75]. The authors
speculated that a reasonable explanation to these results would be
that the afﬁnity of gp120 to the co-receptor governs the length of time
in which the C-inhibitory peptides can bind their NHR targets. Indeed,
later on, it was revealed that the sensitivity to Fuzeon and a co-
receptor antagonist is modulated by two determinants: the afﬁnity of
the gp120 co-receptor interaction, and the availability or expression
level of the co-receptor [65]. These in turn correlated to the fusion
kinetics. These results conﬁrmed previous speculation that co-
receptor afﬁnity and expression level modulate the kinetic window
in which the ENV is sensitive to Fuzeon. Additionally, in 2004 it was
observed that in some HIV-1 patients prior to peptide treatment,
resistant strains emerged. These strains did not contain anymutations
in the NHR in contrast to a number of substitutions in the CHR and
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peptide does not merely depend on the CHR afﬁnity to the NHR but
rather involves other thermodynamic determinants. The authors
hypothesized that the resistance mechanism of these virus strains
depends on reducing the pre-hairpin conformation time window.
They suggested a model in which sequences from both gp120 (co-
receptor binding regions) and gp41 modulate the kinetics of six helix
bundle formation thereby shortening the time in which the CHR-
peptides can interact with their NHR targets. Fuzeon was able to block
the interaction of gp120–CD4 complexes with the CXCR4 co-receptor
[77] and peptides derived from the co-receptor binding site in gp120
competitively inhibited the activity of Fuzeon [68,78]. These results
help to explain the increased sensitivity of CXCR4-speciﬁc HIV-1
isolates to Fuzeon and propose the co-receptor binding site in gp120
as a target for the peptide during viral entry.
5.5. Targeting the N-terminus of gp41
The C-terminus of Fuzeon overlaps with the hydrophobic MPER
which contains the epitope for the 2F5 monoclonal antibody. A crystal
structure of the monoclonal antibody 2F5 bound to its corresponding
epitope demonstrated that this binding is based on electrostatic
interactions creating an elongated structure [52]. This type of
interaction produces a highly unbound hydrophobic face of the
epitope. The authors suggested that this hydrophobic face is occluded
by other hydrophobic gp41 regions. Later, several studies provided
evidence that the interaction between FP or its proximal region and
the MPER domains of gp41 increased the efﬁcacy of 2F5 binding to its
MPER epitope [24,32]. These observations suggest the N-terminus of
gp41 as a potential target for Fuzeon during viral entry. Fuzeon may
prevent the self-interaction of the N-terminus of gp41 in the early
fusion steps while gp41 is extended; alternatively, it may block the
interaction of the MPERwith the N-terminus of gp41 in the late fusion
steps.
6. HIV-1 fusion inhibitors are important candidates in AIDS therapy
Fuzeon was approved as a drug by the food and drug administra-
tion (FDA) in March 2003 [79]. It created a new therapeutic category
of anti HIV-1 drugs: entry inhibitors [80]. It shows good antiviral
potency and long-term safety in clinical use. However, it must be
subcutaneously injected twice a day, which is highly inconvenient.
The virus exhibited wide ranging susceptibilities to Fuzeon, and the
compound has a relatively low genetic barrier for resistance.
Therefore, it should only be applied as part of a combinatorial drug
application with others antiretroviral agents [81].
Recent progress in the ﬁeld of HIV therapy has led to alternative
entry inhibitor compounds that are generally divided into three
classes: (i) attachment inhibitors, (ii) co-receptor binding inhibitors,
and (iii) fusion inhibitors. Many of these inhibitors are at different
stages in clinical trials [82]. Until now, fusion inhibitors have been the
most successful and promising class of HIV entry inhibitors. For
several compounds, the identiﬁed targets are regions within the
ectodomain of gp41. In addition to the ﬁrst generation fusion
inhibitor, Fuzeon, a rational peptide design approach has led to
other attractive peptides. The second generation fusion inhibitor T-
1249was designed from the CHR region. It is more potent than Fuzeon
and preserves its potency to Fuzeon resistant strains [83]. Recently, a
series of more potent third generation fusion inhibitors were
designed. These include T-2635, which has an improved helical
structure that increases stability and activity against both wild type
HIV-1 and fusion inhibitor resistant variants [84,85]. A natural HIV-1
inhibitor, designated as VIRIP, was recently discovered. This is a 20-
residue peptide which targets gp41 fusion peptide. The peptide is
potent against a wide variety of HIV-1 strains including those resistant
to current antiretroviral drugs [86]. Clinical trials with VIRIP providesa proof of concept that fusion peptide inhibitors suppress viral
infection in human patients, and offer prospects for the development
of a new class of drugs that prevent the virus from anchoring to and
infecting host cells [87].
7. Conclusions and prospects
Three decades have passed since the discovery of AIDS and still it is
amajor concern for public health. Its causing agent, the HIV retrovirus,
was detected and was extensively studied throughout the years to
seek how it spreads the disease. In order to start an infection cycle, the
virus delivers its genetic material into the host cell by merging both
viral and host cell membranes into one. This step is orchestrated by
the trimeric HIV ENV similarly to many other viruses. Its peripheral
subunit, gp120, mediates host tropism, while its transmembrane
subunit, gp41, mediates the actual membrane fusion. Compounds that
interfere with membrane fusion induced by viruses are important to
reveal themechanism of this process, and to develop drugs that would
inhibit it. The discovery of gp41 derived peptide, Fuzeon, led to a
successful achievement of these two goals. Fuzeon was synthesized
from the C-terminal part of the ectodomain gp41. It was the ﬁrst
peptide that showed very potent inhibition of HIV infection and
created a new therapeutic category of anti HIV-1 drugs: entry
inhibitors. Initially, it was believed that the sole inhibitionmechanism
of the peptide is targeting the NHR region of gp41 during the
formation of the pre-hairpin conformation. This would subsequently
prevent the formation of the hairpin conformation leading to
inhibition of membrane fusion. Only recently, accumulating evidence
suggest a multifaceted nature for Fuzeon in inhibiting HIV infection.
In this review we provided a comprehensive summary of the
different modes of action of Fuzeon, suggesting multiple targets on
the viral ENV because of its unique sequence (Fig. 3). The peptide's
sequence is comprised of two regions in gp41 (CHR and MPER) that
are important to its fusogenicity. Early on, it targets the gp120 co-
receptor binding sequence, blocking the interaction of gp120–CD4
complexes with the CXCR4 co-receptor. Later, it targets the NHR in
gp41 pre-hairpin conformation thus preventing the conversion into
the hairpin conformation. Lastly, it has an additional inhibitory mode
of action involving its C-terminal region and membrane binding. This
alternative mode of action might involve interfering with the
assembly of gp41 trimers (by binding the MPER region), thus
preventing fusion pore expansion to arrest the fusion process.
Fuzeon was approved by the FDA in 2003 for AIDS patients and
was considered a promising drug, but resistant strains quickly
emerged. Today there are alternative compounds that are at different
stages in clinical trials. Besides its important clinical contribution, the
discovery of this peptide heralded a new era of thinking within the
ﬁeld of membrane proteins. The use of peptidic fragments from a
membrane protein that interfere with its function is now an emerging
and promising approach for understanding protein structure and
function.
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